Rakhi Naik MD, MHSAssociate Director for Hematology, Hematology/Oncology Fellowship Program, Assistant Professor of Medicine, Hematology, Johns Hopkins Medicine, Baltimore, Maryland
Dr. Naik graduated from Duke University with a degree in Biomedical and Electrical Engineering and received her MD from Cornell Medical School. She also holds a Masters in Health Sciences (MHS) from the Johns Hopkins Bloomberg School of Public Health. Dr. Naik has been at Hopkins since 2006, serving as Osler residency housestaff, hematology fellow, and Assistant Chief of Service (Chief Resident) prior to being recruited to faculty as an Assistant Professor in May 2013. She currently serves as the Associate Director for Hematology for the Hematology-Oncology Fellowship Program.
Dr. Naik’s primary research involves the genetic epidemiology of sickle hemoglobin disorders, with the goal of informing genetic counseling, screening and treatment guidelines. She is currently involved in several large-scale epidemiologic efforts using National Heart, Lung, and Blood Institute (NHLBI) population study cohorts to define clinical complications of sickle cell trait, including venous thromboembolism, renal disease, cardiovascular disease, and stroke.
Dr. Naik serves on the American Society of Hematology (ASH) Committee on Training and is a member of the ASH Recruitment and Retention Working Group, which aims to increase the recruitment of trainees into benign hematology.
Recent Contributions to PracticeUpdate:
- Management of Acute and Chronic Pain in Sickle Cell Disease
- Coagulopathy and Antiphospholipid Antibodies in Patients With COVID-19
- Prevalence of VTE in Patients With Severe Novel Coronavirus Pneumonia
- COVID-19: Through a Hematologic Filter
- tPA for COVID-19–Associated ARDS
- D-Dimer Is Associated With Severity of COVID-19
- ASH 2019 Guidelines for Sickle Cell Disease: Cardiopulmonary and Kidney Disease
- Trends and Factors Affecting the US Adult Hematology Workforce
- 2019 Top Stories in Benign Hematology: Novel Drugs in Sickle Cell Disease
- Treatment of Post-Transfusion Hyperhemolysis Syndrome in Sickle Cell Disease With Tocilizumab